VERA THERAPEUTICS, INC.

(VERA)
  Report
Delayed Nasdaq  -  05/23 04:00:00 pm EDT
14.85 USD   -12.80%
05/20Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
GL
05/20Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
AQ
05/20VERA THERAPEUTICS : Effect of Atacicept on Renal Function in SLE Patients
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors

12/14/2021 | 07:31am EDT

Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufacturing experience

BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball Hall to its board of directors.

Ms. Hall is a seasoned executive and a chemistry, manufacturing, and controls (CMC) expert. Formerly holding leadership positions at Genentech and Amgen, she is currently president and chief operating officer of Abzena, a biopharmaceutical focused contract development and manufacturing organization (CDMO).

“We’re honored to welcome Kimball to our board of directors,” said Marshall Fordyce, MD, founder and CEO of Vera Therapeutics. “Over her decades of pharmaceutical and biotech industry experience, Kimball has shown the leadership required to translate high-level vision into practical and successful business strategies. She has demonstrated success leading cross-functional teams and projects developing novel biologic therapies, including the successful transition from clinical to commercial stage. Kimball’s experience and direction will help Vera advance our core objectives and ultimately improve medical treatment for patients suffering from serious immunological diseases. On behalf of the entire Vera board, I look forward to Kimball’s contributions.”

Prior to her current role at Abzena, Ms. Hall held several executive positions at Genentech, Inc., a member of the Roche family, most recently as senior vice president, global head of drug substance manufacturing and a member of the Genentech executive committee. Responsible for seven internal sites and 27 external manufacturing locations, she supported five commercial product launches, built a strong quality and safety culture, and established small-volume production. Prior to joining Genentech, Ms. Hall spent 16 years at Amgen, a biotechnology company, most recently as vice president of manufacturing.

“Vera stands out among the many companies pursuing therapies for immunologic diseases,” said Ms. Hall. “The company’s lead clinical-stage candidate, atacicept, is potentially disease modifying for people who suffer from kidney disease and lack effective treatments. I’m thrilled to join Vera’s board of directors and look forward to working with Vera’s management team and the board to grow the company and continue to move atacicept forward for the patients who are waiting for improved medical treatments.”

Ms. Hall has held a variety of board and advisory board positions, including as a member of Genentech’s patient access board and as an advisor to Genentech’s global women’s professional organization. She holds a bachelor’s degree in microbiology from the University of Washington.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus. For more information, please visit www.veratx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Kathy Vincent
Greig Communications, Inc.
kathy@greigcommunications.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f96d8e68-65ff-4a18-92e5-148678704f4d


All news about VERA THERAPEUTICS, INC.
05/20Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentatio..
GL
05/20Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentatio..
AQ
05/20VERA THERAPEUTICS : Effect of Atacicept on Renal Function in SLE Patients
PU
05/16VERA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/16Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/16Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Res..
GL
05/12Certain Options of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on..
CI
05/12Certain Class A Common Stock of Vera Therapeutics, Inc. are subject to a Lock-Up Agreem..
CI
05/05Vera Therapeutics to Present at Upcoming Conferences in May 2022
GL
05/03Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Associati..
GL
More news
Analyst Recommendations on VERA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -80,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,88x
Yield 2022 -
Capitalization 402 M 402 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 18
Free-Float 90,7%
Chart VERA THERAPEUTICS, INC.
Duration : Period :
Vera Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 14,85 $
Average target price 33,40 $
Spread / Average Target 125%
EPS Revisions
Managers and Directors
Marshall W. Fordyce President, Chief Executive Officer & Director
Sean P. Grant Chief Financial Officer
Konrad Hans von Emster Chairman
Celia Lin Chief Medical Officer
Tom Doan Senior Vice President-Development Operations
Sector and Competitors
1st jan.Capi. (M$)
VERA THERAPEUTICS, INC.-44.42%402
MODERNA, INC.-45.81%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-27.91%38 497
SEAGEN INC.-9.87%25 649
ICON PUBLIC LIMITED COMPANY-29.74%17 688